tbuckley/cabot-search huggingface dataset:
Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: Case study and review of the literature
Authors: Marijke Eurelings, Catharina J.M. Frijns, Frank J.F. Jeurissen
Journal: Neuro-Oncology (2002)

Parathyroid carcinoma is an uncommon malignancy.Of the fewer than 400 cases reported, most have been cases of producing parathyroid carcinoma with accompanying hypercalcemia.Only 13 patients with nonproducing parathyroid carcinoma have been described.Nine of these 13 patients had metastatic disease.We report a patient with i.c.metastasis.Distal metastases of producing parathyroid carcinoma are treated surgically to prolong survival and prevent complications of hyperparathyroidism and hypercalcemia.One half of the patients with producing parathyroid carcinoma die within 5 years, mostly because of the complications of hypercalcemia.Nonproducing parathyroid carcinoma compares unfavorably with producing parathyroid carcinoma in terms of tumor progression and prognosis.Few data on choice of therapy in nonproducing parathyroid carcinoma are available.We treated our patient with a combination of radiotherapy and chemotherapy.Treatment was followed by an unexpectedly prolonged survival of 31 months after diagnosis of metastatic disease.Neuro-Oncology 4, 44-48, 2002 (Posted to Neuro-Oncology [serial online], Doc.01-023, October 3, 2001.URL <neuro-oncology.mc.duke.edu>)W e report a patient who had nonproducing parathyroid carcinoma with painful ophthalmoplegia from i.c.metastasis.We treated this patient with cranial radiotherapy (5 3 400 cGy in 1 week) followed by 3 cycles of chemotherapy once every 3 weeks, with a combination of cisplatin (100 mg/m 2 on day 1) and etoposide (120 mg/m 2 on days 1, 2, and 3).In view of the extreme rarity of the tumor, clinical trials to test different treatment modalities are not feasible.Therefore, the development of future treatment strategies depends on anecdotal reports.
Intussuscepting Hemangiomas of the Gastrointestinal Tract: Report of Case and Review of the Literature
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
L'Iris, Étude physiologique sur la pupille et ses centres moteurs.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer
Authors: G. C. de Gast, F. A. Vyth-Dreese, W. Nooijen, C. J.C. van den Bogaard, J. Sein, M. M.J. Holtkamp, G. A.M. Linthorst, J. W. Baars, J. H. Schornagel, S. Rodenhuis
Journal: Journal of Clinical Oncology (2002)

Repeated high-dose chemotherapy (HDCT) followed by peripheral-blood progenitor cell (PBPC) transplantation can induce a complete remission in patients with metastatic breast cancer sensitive to standard chemotherapy (CT), but the majority of patients relapse within 1 to 2 years. The immune system is seriously compromised after HDCT, which precludes the development of effective immunotherapy. We investigated whether autologous lymphocytes, reinfused after HDCT, could induce a rapid recovery of T cells.Three patients were monitored for immune recovery without reinfusion of lymphocytes. In the next 11 patients, stem cells were harvested after CT + granulocyte colony-stimulating factor (G-CSF) and lymphocytes were harvested after CT + granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2. These patients received stem cells and G-CSF after the first HDCT; stem cells, G-CSF, and lymphocytes after the second; and stem cells, GM-CSF, and lymphocytes after the third HDCT.Patients not receiving lymphocyte reinfusion had a very slow recovery of lymphocytes. In particular, CD4 counts remained low (< 200/microL for 9 months). Lymphocyte reinfusion had a significant effect on the recovery of lymphocytes, T cells, and CD8+ T cells (normalized on day 25). Recovery of CD4+ T cells was significantly accelerated by lymphocyte reinfusion and GM-CSF, leading to counts of 500/microL at 25 days.Lymphocyte reinfusion with G-CSF had a significant effect on the recovery of CD8+ T cells, whereas rapid recovery of CD4+ T cells required lymphocyte reinfusion and GM-CSF, which possibly acts as a survival factor through activation of antigen presenting cells. Whether the rapid recovery of CD4+ and CD8+ T cells prevents or delays relapse of the disease should be further investigated.
Breast-feeding. Time to teach what we preach
Authors: G L Freed
Journal: JAMA (1993)

IN THE<i>Healthy People 2000</i>report,<sup>1</sup>the US Secretary of Health and Human Services set as new goals for breast-feeding in the United States to "increase to at least 75% the proportion of mothers who breast-feed their babies in the early post-partum period and to at least 50% the proportion who continue breast-feeding until their babies are five to six months old." Importantly, these goals were set for the nation as a whole, without reference to any ethnic or economic subgroup. This conveys the message that breast-feeding will benefit all our nation's children, not just those of a defined population. The report goes on to state that overcoming barriers to successful breast-feeding will require "public and professional education and improved support from health care providers...." In recognition of the beneficial effects of breast-feeding to infants and of the role physicians can play in its promotion, the American Academy of
Comment on: Effect of a nicotine-free inhalator as part of a smoking cessation programme
Authors: P. Caponnetto, F. Cibella, A. Fisichella, R. Polosa
Journal: European Respiratory Journal (2012)

The authors in their methodology described to be using the Fagerstro ¨m Test for Nicotine Dependence (FTND), and it would be of interest also to know whether estimates with FTND as dependency parameter gave a similar result.Also, it would be of interest to know the actual duration of nicotine-free inhalator use in each of the two groups (median and range), and whether the concordance with the smoking cessation intervention (buproprion and high-dose nicotine patch) differed in the two groups, if these data are available.
TRAUMATIC SURGERY PROBLEMS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physicians for Human Rights
Authors: Aaron Levin
Journal: Annals of Internal Medicine (2001)

Current Clinical Issues20 March 2001Physicians for Human RightsAaron LevinAaron LevinSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-6-200103200-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Physicians for Human Rights (PHR) began as a handful of souls dedicated to alleviating suffering in distant lands in the mid-1980s and went on to share the Nobel Prize for Peace in 1997. By then, PHR had been active behind the scenes for barely a decade and was recognized for just one part of its varied work. First in Latin America and since then in Southeast Asia, Africa, the Middle East, the Balkans, and the United States, this small alliance of health professionals has spent nearly 15 years monitoring and advocating for human rights around the world.Why should physicians, ... Author, Article, and Disclosure InformationAuthors: Aaron LevinAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMedical Activism and Environmental Health 20 March 2001Volume 134, Issue 6Page: 537-540KeywordsArabic peopleHealth careHispanic peopleIntelligenceMedical ethicsPathologistsPrevention, policy, and public healthRacial and ethnic discriminationRacial and ethnic issuesSocioeconomic status ePublished: 20 March 2001 Issue Published: 20 March 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide
Authors: U Eckhardt
Journal: Hepatology (1996)

The peptidomimetic thrombin inhibitor CRC 220, 4-methoxy-2,3,6-trimethylphenylsulfonyl-L-aspartyl-D-4-amidinop henylalanyl- piperidide, is taken up into isolated rat hepatocytes through active, carrier-mediated transport. This uptake is inhibited by bile acids. Functional expression in Xenopus laevis oocytes was performed to identify the transport system responsible for the hepatocellular CRC 220 uptake. Injection of poly(A)+RNA in X. laevis oocytes resulted in a two- to three-times higher uptake of CRC 220, compared with uninjected or water-injected control oocytes. Taurocholate (200 mumol/L) inhibited this uptake completely. No uptake of the peptidomimetic thrombin inhibitor was observed, when X. laevis oocytes were injected with complementary RNA (cRNA) encoding either the cloned rat liver Na+- dependent taurocholate transporter Ntcp, the renal oligopeptide carrier rhaPT or the intestinal oligopeptide transporter PepT1. However, after injection of cRNA of the cloned rat liver Na+-independent organic anion transporting polypeptide oatp, a specific and saturable CRC 220 uptake was observed (Michaelis-Menten constant 29.5 mumol/L). Cis-inhibition with known oatp-substrates, e.g., 20 mumol/L Bromsulphalein (BSP), 2007 mumol/L taurocholate and 2007 mumol/L cholate, occurred in oatp-expressing X. laevis oocytes, whereas substrates of the two peptide carriers as well as dipeptide- and single-amino acid constituents of the thrombin inhibitor itself lacked any significant inhibitory effects. These data show that the modified dipeptide CRC 220 is a highly selective substrate of the organic anion transporting polypeptide oatp in the basolateral plasma membrane of rat hepatocytes.
Edward Nettleship (1845-1913) Veterinarian-Dermatologist-Ophthalmologist-Geneticist
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Congenitally hypothyroid mice yield clues for man
Authors: G. McBride
Journal: JAMA (1982)

What appears to be a good animal model for 80% of cases of human congenital hypothyroidism is being studied intensively at The Jackson Laboratory, Bar Harbor, Me, and a dozen or so other laboratories. Wesley Beamer, PhD, a staff scientist at The Jackson Laboratory, first discovered the mutation around the end of 1975 in a female laboratory mouse, although he first thought it was a deficiency of growth hormone. Further breeding of the mouse and its progeny led to the conclusion that the phenotype was due to an autosomal recessive gene. Eva Eicher, PhD, also of the laboratory, then mapped the gene to chromosome 12 in the mouse. (The gene or genes that may be related to some or all cases of human congenital hypothyroidism have not been mapped.) Thyroid glands in the affected (<i>hyt/hyt</i>) mice are of small size and very hypoplastic, similar to those in 80% of infants
Journal für Hirnforschung, Berlin
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stroke
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tuberculosis Management
Authors: Maurice L. Sievers
Journal: JAMA (1976)

<h3>To the Editor.—</h3> The recent communications by Furey and Stefancic (235: 168, 1976) and by McConville and Rapoport (235:172, 1976) provide excellent information regarding the present management of tuberculosis. However, the perspective is somewhat limited, perhaps because of the metropolitan purview of the authors of both the former (Chicago) and the latter (Baltimore) articles. Their stress that currently tuberculosis is primarily an urban disease has merit, but it ignores the fact that many tribes of American Indians, who reside on isolated<i>rural</i>reservations, continue to have high rates of tuberculosis<sup>1,2</sup>(despite a marked reduction in recent years). In addition, in their discussion of the toxicity of isoniazid, McConville and Rapoport aptly described the small risk of isoniazid hepatotoxicity but, with that circumscribed viewpoint, omitted at least one other important toxic effect—the great potential of massive intentional or accidental isoniazid overdosage to produce disturbed consciousness, intractable convulsions, and death.<sup>2,3</sup>
Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
Authors: C. Barone, G. Brandi, B. Daniele, E. Villa, S. Leo, F. Di Fabio, G. Aprile, M. Colombo, A. Sobrero, G. Giannelli, C. Porta, G. Cabibbo, A. Zhu, J. Blanc, T. Okusaka, I. Chau, P. Abada, L. Yang, D. Pastorelli
Journal: Annals of Oncology (2015)
Noble Metals: A Toxicological Appraisal of Potential New Environmental Contaminants
Authors: Paul E. Brubaker, John P. Moran, Kenneth Bridbord, F. Gordon Hueter
Journal: Environmental Health Perspectives (1975)

The public health benefits expected by reducing known hazardous emissions from mobile sources should not be compromised by increasing levels of other potentially hazardous unregulated emissions. Catalytic converters are going to be used to meet the statutory requirements on carbon monoxide and hydrocarbon emissions from light duty motor vehicles. Platinum and palladium metals are the catalytic materials to be used in these emission control devices. Preliminary experimental evidence and analysis of the impact of these control devices on the future use and demand for platinum indicates that this metal may appear at detectable levels in the environment by the end of this decade. At the present time, platinum and palladium are not present in the public environment and represent potentially new environmental contaminants as a consequence of use of this new abatement control technology. There is relatively little information available to adequately assess the potential health hazards that may be associated with exposure to these metals and their compounds. Analysis of the environmental problems and concerns associated with possible new environmental contaminants are discussed. Limited estimates are made on community exposure by use of a meteorological dispersion model. Biodegradation potential and attention is also given to the limited toxicological information available.
Martin rodbell obituary
Journal: Environmental Health Perspectives (1999)

Martin Rodbell, recipient of the Nobel Prize in Physiology or Medicine in 1994, passed away 7 December 1998 after a long illness. Rodbell had a long and distinguished career in research and senior leadership positions at the National Institutes of Health. At different times in his career, he conducted research at the National Heart Institute, the National Institute of Arthritis and Metabolic Diseases (NIAMD), and the National Institute of Environmental Health Sciences (NIEHS). He served as Scientific Director of the NIEHS from 1985 to 1989. In 1994 he shared the Nobel Prize in Physiology or Medicine with Alfred Gilman, Professor and Chairman in the Department of Pharmacology at University of Texas Southwestern Medical Center in Dallas, for their work on G-proteins, a key component of the communication system that regulates cellular activity. Rodbell was the fifth NIH intramural scientist to be awarded a Nobel Prize.
Somnambulating into a paradigm shift--World Changes: Thomas Kuhn and the Nature of Science
Authors: H. A. Rashkis
Journal: JAMA (1994)

<h3>To the Editor.</h3> —The very fine review by Richard Manning<sup>1</sup>of<i>World Changes: Thomas Kuhn and the Nature of Science</i>, edited by Paul Horwich, appeared in the same issue of<i>JAMA</i>as a group of letters, "Managed Care, Mental Health, and the Marketplace," relating to a Commentary by Drs Jellinek and Nurcombe.<sup>2</sup>I wondered what Thomas Kuhn would have thought of the debate. Unable to speak for Professor Kuhn, I note his interest in language, communication, paradigm, and paradigm shift. I would suppose him to say that insurers and physicians think and speak from paradigms so dissimilar that communication and the achievement of like-mindedness is impossible. Even if they use the same words (with differing intent), they talk past each other. This is not surprising: insurers are in business and their only purpose is to make increasingly larger profits. Physicians expect to earn a good living but have